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Abstract—Tasmanian devil facial tumor disease (DFTD) is a 
naturally occurring contagious cancer which is transmitted as 
a clonal cell line between devils. The malignant cell line evolved 
from a Schwann cell or precursor prior to 1996 and since then 
has undergone continuous division without exhausting its 
replicative potential, suggesting a profound capacity for self 
renewal. It is therefore important to elucidate whether DFTD 
may have a stem cell origin. Deciphering the pathways 
regulating DFT cell proliferation and survival could lead to 
increased understanding of this transimissible cancer and to 
the development of successful therapies to halt the disease. We 
investigated whether DFT cells have originated from 
transformed stem cells by measuring the expression levels of  
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thirteen genes characteristic to embryonic stem and/or 
pluripotent germ cells. No differences in gene expression were 
observed between DFT cells and peripheral nerve controls, and  
therefore our results provide additional support for Schwann 
cell or peripheral nerve origin of DFTD. Although our dataset 
is preliminary, it does not suggest that DFTs have cancer stem 
cells (CSCs) origin. We provide details of further experiments 
needed to ultimately confirm the role of cancer stem cells in 
DFTD progression. 
 




Malignant tumors have been described as heterogeneous 
populations of cells, where cells with different biological 
functions compete for resources within the 
microenvironment of the neoplasm [1-3]. Cells with the 
highest proliferative potential, immune evasion capacity and 
adaptability have the highest chance of survival and hence 
confer significant evolutionary benefits [1]. The mechanism 
underlying cancer evolution has long been of interest, and 
two mutually non-exclusive, but concurrent theories have 
been developed to describe neoplasm progression: 
(i) The stochastic or clonal evolutionary theory posits that 
during tumor development a transformed cell or cells gain 
unlimited proliferative capacity, and hence produce 
uncontrolled cell growth. The subsequent accumulation of 
random mutations result in a heterogeneous cell 
subpopulations within the tumor, and the concomitant 
selection of sub clones drives tumor evolution [4]. 
Importantly, according to the stochastic or clonal 
evolutionary theory any of the cancer cells can participate in 
tumor growth, development and recurrence [5]. 
 
(ii) A recently resurrected theory, the hierarchical model or 
cancer stem cell (CSC) hypothesis [6, 7] also traces tumor 
origins to single mutated cells with unlimited proliferative 
potential, but in contrast to the clonal model, the cells 
possess stem cell qualities [8]. The concept of CSCs 
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assumes that they arise from transformed stem cells (either 
tissue stem cells or their immediate progeny) via 
accumulation of genetic modifications (mutations and 
epigenetic alterations) [9], or from de-differentiation of 
somatic cells via acquiring stem cell characteristics [10], 
and the development of the tumor results from the clonal 
evolution of the CSC population [11]. The multipotent 
nature of these cells results in cellular heterogeneity within a 
tumor. As a result of hierarchical differentiation, the tumors 
contain cellular subcomponents that retain key stem cell 
properties, but the majority of the progeny cells do not 
possess self-renewal potentials and hence do not contribute 
to tumor progression [12]. In contrast to the clonal evolution 
theory, the cancer stem cell hypothesis postulates that only 
the CSCs are responsible for tumor growth, participate in 
tumor progression, drive metastasis and tumor reoccurrence 
[13]. Recently several human and animal studies have 
reported evidence that cancer stem cells are responsibly for 
the growth of certain brain, skin, intestinal and bone tumors 
[14-18]. Although both evolutionary theories have attracted 
ample advocates and critics [6, 13, 19, 20], the validity of 
either still remains to be resolved. 
 
A recent paper by O’Neill [21] suggested that transmissible 
animal tumors might have originated from stem cells and 
hence provide unique models to study cancer stem-cell 
processes. Canine transmissible venereal tumor (CTVT) and 
Tasmanian devil facial tumor (DFT) are two, naturally 
occurring clonally transmissible cancers [22]. The two 
diseases produced by these transmissible cancers share 
similar etiology; both of them originated from a rogue cell-
line, and can be transplanted as allografts between unrelated 
hosts by physical transfer. CTVT is a globally distributed 
sexually transmitted tumor of dogs. The disease possibly 
arose thousands of years ago from a single wolf, and 
therefore CTVT is considered to be the oldest known 
somatic cell line [23, 24]. Devil Facial Tumor Disease 
(DFTD) is a more recently emerged infectious disease of 
Tasmania devils, the world largest remaining carnivorous 
marsupial [22, 25, 26]. The first case of DFTD was 
observed in 1996 in the north-eastern Tasmania [25] where 
animals were sighted showing some of the hallmark gross 
pathologies associated with what was later defined as 
DFTD. The disease is characterized by large ulcerating 
lesions around the mouth and the face of the affected 
animals [27]. This aggressive cancer is transmitted by biting 
between the devils during sexual and feeding interactions 
[28]. DFTD indiscriminately affects both female and male 
devils and generally causes death within six month of the 
appearance of initial lesions. Due to the rapid progression 
and transmission of the disease, the Tasmanian devil 
population has declined by 80% over the past 15 years and 
may face extinction in the wild within 25-35 years [25, 29]. 
Cytogenetic analyses have revealed that DFTD is caused by 
a rogue cell line [26] most likely originated from Schwann 
cells of the peripheral nerve sheath [27, 30]. Devil Facial 
Tumor (DFT) cells possess a highly rearranged genome, 
characterized by tumor-specific complex translocations and 
chromosomal rearrangements [26, 31]. The clonal nature of 
DFTs have been supported by both large-scale genetic [30, 
32] and immunohistological [27] analyses. Furthermore, the 
analyses of microsatellite markers and functionally 
important genes, such as the Major Histocompatibility 
Complex (MHC) revealed that DFT cells in different 
individuals are genetically identical, demonstrating the 
stable nature of the tumor [22, 30, 32-34]. However, three 
recent studies have described the existence of four, closely 
related but karyotypically distinct DFT strains, suggesting 
that the tumor is clonally evolving via stepwise mutational 
changes [32, 35, 36]. Since their emergence in 1996 [26] 
DFT cells have undergone continuous division and 
propagation in thousand’s of devils without exhausting their 
replicative potential, suggesting an apparent capacity of self 
renewal. Here we provide preliminary data on the possible 
existence of CSCs in devil facial tumors and discuss the 
necessary experiments to test whether a subpopulation of 
self-renewing CSCs exists in DFTD. 
 
II. MATERIALS AND METHODS 
 
A. RNA extraction and quantifying gene expression by 
quantitative RT-PCR 
RNA was extracted from four spleen, seven peripheral 
nerve and nine primary tumor samples using a combination 
of Trizol (Sigma, St. Louis, MO) and Qiagen RNeasy mini 
kit (Qiagen, Germantown, MD). RNA quality and quantity 
were measured on an Agilent 2100 BioAnalyzer (Agilent, 
Santa Clara, CA). Genomic DNA was removed from the 
RNA samples by the DNAse I AMPD1 kit (Sigma, St. 
Louis, MO) and cDNA was synthesized with the QuantiTect 
Reverse Transcription Kit (Qiagen, Germantown, MD). 
Thirteen genes (AK3, BMI1, DPPA4, FGF14, FZD7, 
GABRB3, GGTLA5, GPC4, NANOG, Oct-4, RB1, SCNN1A, 
SOX2) previously demonstrated to be significantly 
expressed in embryonic stem cells and human pluripotent 
germ cell tumors [34-36] were selected for quantitative real-
time PCR analyses (Table 1). Gene-specific primers 
spanning across exon boundaries were designed based on 
the Tasmanian Devil genome annotation (Ensembl [29]), 
using the Primer3Plus website 
(http://www.bioinformatics.nl/ 
cgi-bin/primer3plus/primer3plus.cgi) (Table 1). Two genes, 
GAPDH and GUSB were used as normaliser genes 
following the description of Murchison et al. [19, 27] (Table 
1). The Q-PCR reactions were performed on the 
RotorGene6000 (Qiagen, Germantown, MD) in 15 µl total 
volume, containing 7.5 µl of Qiagen 2xQuantifast Sybr 
Green PCR master mix (Qiagen, Germantown, MD), 0.25-
0.5 µM forward and reverse primers (optimal primer 
concentrations were established for each primer 
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combinations) and 1 µl of cDNA (5ng/µl concentration). 
Reverse transcriptase negative and cDNA negative samples 
were run alongside the cDNA samples as controls to detect 
genomic DNA contamination and primer-dimer formations. 
Q-PCR conditions were established according to the 
manufacturer protocol: 95º C for 5 min denaturation 
followed by 40 cycles of 95º C for 15 s and 60º C for 30 s 
(annealing temperature, AT). Fluorescence signal was 
acquired at the AT. To evaluate the specific amplification a 
final melting curve analysis (from AT up to 99° C) was 
added under continuous fluorescence measurements. 
B. Statistical analyses 
Relative quantifications of gene expressions were 
performed using sample-crossing points, and data was 
analysed with the Rotor Gene 6000 software 1.7. (Qiagen, 
Germantown, MD), applying the “second derivative 
maximum” method [38]. The Excel application Best-Keeper 
[39] was used to check the data for statistical significance, 
normality and reliability, and the normaliser gene GUSB 
was chosen as reference based on BestKeeper calculations 
[39]. The program Rest [40] was used to calculate the 
normalised fold change of the target gene compared to the 
reference gene. Statistical significance (P < 0.05) was 
determined by a Pair-Wise Fixed Reallocation 




AK3, FGF14, GGT5, GPC4, RB1 and SOX2 genes were 
not differentially expressed between DFT and peripheral 
nerve samples (Table 2.). Due to low expression of the 
target transcripts, the expression levels of BMI1, DPPA4, 
FZD7, GABRB3, NANOG, Oct-4, SCNN1A were below the 
linear range of detection, showing that these genes are not 
expressed in DFT, peripheral nerve and spleen samples. 
Five genes, SOX2, FGF14, GPC4, AK3 and GGT5 had 
significantly higher expression in nerves compared to 
spleens (Table 2). Compared to spleen, DFT samples 
showed up-regulation of SOX2, FGF14, GPC4 genes (Table 




Up-regulation and expression of four genes (FGF14, 
SOX2, GPC4 and GGT5, which have previously been 
shown to be expressed in Schwann cells [37-40]) in both 
nerve and DFT samples compared to spleen, adds further 
support for the Schwann cell lineage origin of DFT cells 
[30]. The expression of FGF14 in DFT and peripheral nerve 
cells is not surprising since the protein encoded by this gene 
is involved in a variety of biological processes (not only 
restricted to stem cells) such as tissue repair in response to 
injury, and, hence act as homeostatic factors [41]. Moreover, 
FGF14 also constitutes one of the four genes of intracellular 
fibroblast growth factors (iFGFs), which are important for 
neuronal signal transduction and regulation in the central 
and peripheral nervous systems [37]. 
 
The high expression of SOX2 in both peripheral nerve 
and DFT samples is more intriguing. Apart from being a 
transcriptional factor with an essential role in maintaining 
self-renewal of undifferentiated embryonic stem cells, SOX2 
has also been found to be a marker of immature and 
dedifferentiated Schwann cells [38]. This protein is not 
typically expressed in neural crest stem cells, but is 
specifically turned on in Schwann cells where it plays a 
crucial role in maintaining these cells in an immature state 
[42]. The observed high level of expression of SOX2 in DFT 
cells most likely has an important role in maintaining the 
tumor cells in an undifferentiated state, without undergoing 
neuronal commitment which would lead to the loss of 
proliferative capacity [38, 43]. Schwann cell development 
occurs through a series of transitional embryonic and 
postnatal phases, regulated by signaling pathways with 
characteristic gene expression patterns [42]. A study by 
Murchison et al. [30] showed high expression of genes 
characteristics of immature fetal (SOX2, c-Jun), postnatal 
pro-myelinating (POU3F, MPZ) and myelinating Schwann 
cells (myelin basic protein (MBP), transcription factor 
SOX10, structural myelin genes MPZ, PRX, PMP22), but 
not genes specific to stem cells. The observed gene 
expression patterns might indicate the presence of 
heterogeneous cell populations within DFTs – that is 
Schwann cells at different developmental stages. Another, 
more likely, explanation is that DFT arose due to disruptions 
to developmental pathways in Schwann cells, resulting in 
DFT cells synchronously expressing genes specific to 
different Schwann-cell stages. 
 
In conclusion, although our dataset is preliminary, the 
general lack of up-regulation of stem cell–specific genes 
suggests that DFTD is unlikely to be of stem cell origin. 
Moreover cytogenetic [26, 35, 36] and genetic evidence [30, 
32, 36, 44] also suggest that the progression of DFTD does 
not support the cancer stem-cell theory but follows a clonal 
expansion model [31]. DFTD is a stable, clonal, asexually 
reproducing cell line which undergoes Darwinian evolution 
[4, 32, 45, 46]. Stepwise, somatic-cell mutations and 
sequential selection have most likely resulted in adaptation 
of this somatic pathogen to the tissue microenvironment of 
Tasmanian devils [46]. 
 
However, to univocally confirm or exclude the role of 
cancer stem cells in DFT progression additional experiments 
have to be conducted. For example, ectopic expression of 
Oct4 in tumor cells have been shown to results in 
dedifferentiation and enhanced CSC-like properties [47, 48]. 
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Elevated expressions of Oct4 and Nanog have been reported 
in cancer cell lines and/or primary cancers from various 
human cancers, e.g. adenocarcinoma [49, 50], breast cancer 
[50] and melanoma [48], and the study of Schreiber et al. 
[51] suggested that the expression of these genes actually 
reflected pseudogene activity. Since Nanog and Oct4 work 
together with other key pluripotent factors (e.g. STAT3, LIF, 
FOXD3) a more complex gene expression signature 
analyses (involving several members of the regulatory 
network) could confirm the origins of observed gene 
activity (pseudo- vs functioning protein coding genes). 
 
Furthermore, experimental transfer of DFTD cells 
between devils [52], and xenograft studies in NOD/SCID 
mice [53] have shown that cells from primary tumor culture 
or culture of a previously established xenograft can 
participate in tumor growth and development. In the latter 
study the authors achieved successful tumor growth by 
injecting immunocompromised mice with 1x105-1x107 DFT 
cells. However, none of these studies attempted to select for 
CSCs. Therefore, in order to confirm whether DFT have a 
cancer stem cell origin, an attempt must be made to identify 
a population of potential cancer stem cells from fresh tumor 
samples and/or primary cell cultures. Sarcosphere formation 
and self-renewal assays [18, 54] should be performed 
followed by gene signature analyses of stem cell markers 
[54, 55]. Once a possible stem cell population has been 
identified the ultimate test of CSC behavior would be to 
evaluate the number of cells required from the enriched 
CSCs and from primary DFTs required to initiate a tumor 
when xenotransplanted into immuno-compromised mice. If 
the isolated stem cells and primary tumor cells have the 
same ability to initiate tumors then DFTs most likely do not 
have stem cell origins. 
 
Although our preliminary data indicates DFTs did not 
have increased expression of stem cell markers compared to 
normal tissues, the role of CSCs in DFTD remains an 
unsolved mystery. It is well known that many human and 
animal cancers are resistant to currently available chemo- 
and radiotherapies due to the presence of proliferatively 
quiescent CSCs [10, 56]. Unambiguous identification of a 
possible CSC origin of DFTD is s crucial step to the 
development of successful therapies i.e. bypassing the 
resistance of CSCs [56], or by actively targeting the self-
renewal controlling pathways for the successful eradication 
of CSCs [10], in order to counteract the spread of this 
devastating disease.  
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TABLE 1. GENES IMPLIED IN CSCS AND CORRESPONDING PRIMER SEQUENCES (ALL OLIGONUCLEOTIDES WERE SYNTHESIZED BY 
SIGMA). 
 
 Gene name Function: Primers (5’- 3’) 
1 AK3 
(Adenylate kinase 3) 
Phospohotransferase enzyme with 





MLV insertion region 1 
homolog) 
Oncogene. Necessary for efficient 
self-renewing cell divisions of adult 
hematopoietic stem cells, and nervous 













Mitogenic and cell survival activities, 
involved in embryonic development, 




(Frizzled homolog 7 
Drosophila) 
Transduction and intercellular 
transmission of polarity information 
during tissue morphogenesis and/or in 
differentiated tissues. Involved in 
tumorigenesis via the canonical Wnt 





acid receptor subunit 
beta-3) 
Member of the ligand-gated ionic 
channel family. Serves as receptor for 
gamma-aminobutrytic acid, a major 







like activity 5) 







May play a role in the control of cell 
division and growth regulation. 
F: TGTTCCAACGTCATGAGAGG 
R: TGACCGACTCGATGTTAAAGG 
11 NANOG Transcription factor critically 
involved with self-renewal of 
undifferentiated embryonic stem cells. 




12 Oct-4 or POU5F1 
(Octamer-binding 
transcription factor 4 or 
POU domain, class 5, 
transcription factor 1) 
Critically involved in the self-renewal 






Tumor suppressor, controls the 
proliferation, differentiation, 
and survival of cells, with central role 







sensitive, sodium channels control 
fluid and electrolyte transport across 




(SRY (sex determining 
region Y)-box 2) 
Transcription factor, essential to 
maintain self-renewal of 
undifferentiated embryonic stem cells. 





Used as normalizer gene Primers from [30]: 
F: CTG CTG CCT ATT ATT TCA AGA C 
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TABLE 2. RELATIVE EXPRESSION RESULTS FROM REST ANALYSES. ITERATIONS: 5000, SIGNIFICANCE LEVEL: P < 0.05. UP = UP-
REGULATED, NDE = NOT DIFFERENTIALLY EXPRESSED. 
 





Std. Error 95% Confidence 
Interval 
P Result 
AK3 1.0 0.18 0.01 - 1.89 0.00 - 15.38 0.14 NDE 
FGF14 1.0 3.80 0.29 - 40.71 0.05 - 126.48 0.16 NDE 
GGT5 0.89 0.15 0.01 - 2.58 0.00 - 19.11 0.10 NDE 
GPC4 1.0 0.59 0.07 - 5.63 0.01 - 25.02 0.52 NDE 
RB1 1 1.65 0.17 - 16.17 0.02 - 182.09 0.607 NDE 
SOX2 1.0 2.01 0.33 - 11.79 0.16 - 78.25 0.32 NDE 
PERIPHERAL NERVE VS SPLEEN 
AK3 1.0 7.92 2.29 - 34.92 0.27 - 166.24 0.04 UP 
FGF14 1.0 23.61 2.88 - 106.99 0.57 - 610.24 0.01 UP 
GGT5 0.89 61.86 11.91 - 295.99 2.09 - 522.59 0.01 UP 
GPC4 1.0 72.94 13.98 - 358.79 2.32 - 630.77 0.00 UP 
RB1 1.0 3.18 0.79 - 17.92 0.16 - 40.19 0.22 NDE 
SOX2 1.0 129.69 22.75 - 1,573.49 2.33 - 3,345.03 0.00 UP 
TUMOR VS SPLEEN 
       
AK3 1.0 1.41 0.06 - 14.01 0.01 - 61.06 0.79 NDE 
FGF14 1.0 89.76 6.66 - 1,131.77 0.32 - 2,025.09 0.00 UP 
GGT5 0.89 9.53 0.41 - 154.51 0.09 - 1,153.54 0.14 NDE 
GPC4 1.0 42.85 4.74 - 281.54 0.72 - 1,776.34 0.01 UP 
RB1 1.0 5.24 0.60 - 63.68 0.09 - 217.07 0.201 NDE 
SOX2 1.0 260.93 27.11 - 1,975.31 12.86 - 8,481.22 0.00 UP 
GSTF International Journal of Veterinary Science (JVet) Vol.1 No.1, March 2014
49 © 2014 GSTF
